Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

se of cancer death in the United States, in both men and women.[iii]  It is estimated that more than 140,000 people will be diagnosed with CRC in 2011, and nearly 50,000 people will die from the disease.[iv] Approximately 50 percent of colon cancer patients will be diagnosed with metastases (most commonly to the liver) either at the time of diagnosis or due to recurrent disease.[v]

About Regorafenib

Regorafenib is an investigational oral multi-kinase inhibitor targeting angiogenic, stromal and oncogenic kinases[vi] and is currently being investigated in clinical trials for its potential to treat patients with various tumor types.

Regorafenib is an investigational agent and is not approved by the FDA, EMA or other health authorities. 

Regorafenib is one of several cancer compounds in Bayer's development pipeline.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.  The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related t
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 /PRNewswire/ ... new products for oncology supportive care, announced that its ... been featured in an article on OncLive.com titled, "Study ... and Neck Cancers."  Dr. Steve Sonis , a ... growing demand seen in the oncology community for evidence-based ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... number of costs associated with nonprescription drug manufacturing and ... half years. Certain material costs for plastic bottles and ... time, increasing packaging expenses. Advertising and marketing expenses continue ... of marketers reduced advertising costs in 2009, and in ...
... ERES ) announced today that it will release ... 4, 2010, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
Cached Medicine Technology:Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 2Nonprescription Drugs Cost Structures Fluctuate with Increased Cost of Goods, According to Kline 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:7/31/2014)... July 31, 2014 Eden Lew ... ‘Chuck’ Forman - Crawford Technologies" Scholarship through ... was created to honor the contributions Chuck Forman ... his industry. Chuck lost his battle with cancer ... outstanding, and we are thrilled to see her ...
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... Brickner; “no, not the summer’s hottest metal bands ~ ... Homeostatic Cannabinoid Science ~ Publius’ July Roundup, new ... articles are noted on homeostasis and the cannabinoid system ... modulation of our health and wellness: three directly on ...
(Date:7/31/2014)... 2014 Daily Gossip reveals in its review ... discover some breakthrough weight loss tips. , The author ... recommendations are very simple to implement. Users don’t have to ... no need to start counting calories. , The Flat ... fact created a 12 weeks weight loss program to help ...
(Date:7/31/2014)... 2014 In its latest blog post, ... that having family close by during a stay in rehab ... process is successful, is looking at 11 drug addiction facts ... be. , “While some kids learn a little ... class, the coverage is typically woefully inadequate,” commented Best Drug ...
(Date:7/31/2014)... 2014 Dolce Vite Chocolatto®, world's ... in New York's favorite specialty coffee roaster and DUMBO ... for their commitment to Fair Trade coffee and was ... the new sensation from Italy as the world’s best ... highly popular Italian dessert descended from European Royalty. Prepared ...
Breaking Medicine News(10 mins):Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 2Health News:Eden Lew Recipient of 2014 EDSF Scholarship Honoring Chuck Forman 3Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:New Best Drug Rehabilitation Blog Posts Looks at 11 Drug Addiction Facts they Don’t Teach in School 2Health News:Dolce Vite Chocolatto® - World's Best Thick Dark Italian Hot Chocolate Now Available at NYC's Favorite Cafe Brooklyn Roasting Company 2
... and 24 are smokers, and most say they keep lighting up ... have found that when it comes to quitting, a little bit ... plan in helping women not only keep off the weight, but ... to keep their weight down and for body image reasons, and ...
... in breakthrough creativity in the DTC category, Med Ad ... Wellness as the winner of both the Most Creative ... commenting on the awards, Saatchi & Saatchi Wellness Managing ... advertising icon Helayne Spivak and I knew we needed ...
... diabetes therapy, positively influencing compliance and persistency; electronic ... of dispensing ACCU-CHEK(R) test strips.INDIANAPOLIS, April 24 ... eVoucherRx(TM) pilot program in Florida, designed to make ... their co-pay savings on ACCU-CHEK test strips. The ...
... lowers patients, financial responsibility for their diabetes therapy, ... works in real time at point of dispensing ... today the launch of its new eVoucherRx(TM) pilot ... for patients with diabetes to receive their co-pay ...
... continuing to rise even though the number of cases ... reveals. , The report entitled Cancer incidence, mortality, treatment ... 1994-2004, was compiled by the Northern Ireland Cancer Registry ... Registry (NCRI) of Ireland, in Cork. , This is ...
... help look out for seniors, welfareDETROIT, April 24 ... the lookout and help identify potentially vulnerable elderly customers ... more necessary as Michigan,s economy continues to tumble."Times are ... to do our part to help ensure people don,t ...
Cached Medicine News:Health News:Mind over muscle 2Health News:Saatchi & Saatchi Wellness Wins Creative Awards Honored At 20th Annual Manny Awards 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 2Health News:Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips 3Health News:Survival rates for cancer rise across Ireland 2Health News:Survival rates for cancer rise across Ireland 3Health News:DTE Energy Asks Employees to Help Safeguard Customers 2
... The SR™ Hand Implant System utilizes ... and knee joint replacements. The SR™ ... available in other prostheses including minimal bone ... eroded cartilaginous articular surfaces, retention and/or repositioning ...
For use in implant resection arthroplasty of the trapeziometacarpal joint in cases of rheumatoid, degenerative or post-traumatic arthritis....
The efficient choice for small joint replacement technology -- the Ascension Silicone MCP features a similar design to our PyroCarbon MCP and utilizes the same instrumentation for intra-operative fle...
... Hand Implant System utilizes the same proven ... replacements. The SR™ Hand Implant System ... prostheses including minimal bone resection, surface replacement ... surfaces, retention and/or repositioning of the ligamentous ...
Medicine Products: